The adjunctive role of metformin in patients with mild to moderate ulcerative colitis: a randomized controlled study
Frontiers in Pharmacology · 19.03.2025 · 16
DOI: 10.3389/fphar.2025.1507009 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 19.03.2025. Verfasst von Ammena Y Binsaleh und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy Practice, College of Pharmacy, Princess Nourah bint Abdulrahman University, Riyadh, Saudi Arabia. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 73 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Metformin, hypoglycemic medication, is recognized for its diverse properties and its capacity to influence the inflammatory pathways. Medications with anti-inflammatory and anti-oxidative characteristics have been demonstrated to be able to elicit and sustain remission in ulcerative colitis (UC), chronic inflammatory disorder of the bowel. Studies in both preclinical and clinical settings have looked into the several metabolic pathways via which metformin protects against UC.
Aim
To assess efficacy of metformin as adjunctive therapy in patients with mild to moderate UC.
Methods
This clinical research was double-blinded, randomized, controlled, and involved 60 patients with mild to moderate UC. The participants were randomly assigned to one of two groups (n = 30). The control group was given 1 g of mesalamine three times a day (t.i.d.) for a period of 6 months (mesalamine group). The metformin group was given 500 mg of metformin twice daily and 1 g of mesalamine t. i.d. For a period of 6 months. Patients with UC were assessed by a gastroenterologist using the disease activity index (DAI) both at the beginning of treatment and 6 months thereafter. To evaluate the drug’s biological efficacy, measurements of fecal calprotectin, serum C-reactive protein (CRP), interleukin 10 (IL-10), and nitric oxide (NO) were taken both before and after treatment. Study outcomes Decrease in DAI and change in the level of measured serum and fecal markers.
Results
The metformin group displayed a statistical reduction in DAI ( p = 0.0001), serum CRP ( p = 0.019), NO ( p = 0.04), and fecal calprotectin ( p = 0.027), as well as a significant increase in IL-10 ( p = 0.04) when compared to the mesalamine group. There was a significant direct correlation between DAI and calprotectin (p < 0.0001, r = 0.551), and between DAI and CRP (p < 0.0001, r = 0.794). There was a significant negative correlation between DAI and IL-10 (p = 0.0003, r = 0.371).
Conclusion
Metformin may be an effective adjunct drug in management of patients with mild to moderate UC by decreasing DAI and other inflammatory markers that were involved in the pathogenesis of UC. Clinical Trial Registration identifier NCT05553704.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pharmacy Practice, College of Pharmacy, Princess Nourah bint Abdulrahman University, Riyadh, Saudi Arabia.
- Clinical Pharmacy Department, Faculty of Pharmacy, Tanta University, El-Gharbia Government, Tanta, Egypt.
- Pharmacy Practice Department, Faculty of Pharmacy, Horus University, New Damietta, Egypt.
- Internal Medicine Department, Faculty of Medicine, Mansoura University, Mansoura, Egypt.
- Internal Medicine Department, Faculty of Medicine, Horus University, New Damietta, Egypt.
- Pharmacology and Toxicology Department, Faculty of Pharmacy, Tanta University, Tanta, Al-Gharbia, Egypt.
Zitieren
APA
Binsaleh, A. Y., El-Haggar, S. M., Hegazy, S. K., Maher, M. M., Bahgat, M. M., Elmasry, T. A., Alrubia, S., Alsegiani, A. S., Eldesoqui, M., & Bahaa, M. M. (2025). The adjunctive role of metformin in patients with mild to moderate ulcerative colitis: a randomized controlled study. Frontiers in Pharmacology, 16. https://doi.org/10.3389/fphar.2025.1507009
Vancouver
Binsaleh AY, El-Haggar SM, Hegazy SK, Maher MM, Bahgat MM, Elmasry TA, et al. The adjunctive role of metformin in patients with mild to moderate ulcerative colitis: a randomized controlled study. Frontiers in Pharmacology. 2025;16. doi:10.3389/fphar.2025.1507009
BibTeX
@article{Binsaleh2025,
author = {Binsaleh, Ammena Y and El-Haggar, Sahar M and Hegazy, Sahar K and Maher, Maha M and Bahgat, Monir M and Elmasry, Thanaa A and Alrubia, Sarah and Alsegiani, Amsha S and Eldesoqui, Mamdouh and Bahaa, Mostafa M},
title = {The adjunctive role of metformin in patients with mild to moderate ulcerative colitis: a randomized controlled study},
journal = {Frontiers in Pharmacology},
year = {2025},
volume = {16},
doi = {10.3389/fphar.2025.1507009}
}
EUVIMED